• About Us
  • Add Post
  • Contact
  • Contribute For Us
  • Homepage
  • Our Authors
  • Privacy Policy
What's Hot

Türkiye’s anti-ship missile examined from cellular launcher for 1st time

July 4, 2022

£15bn deal for UK Power Networks collapses after proprietor lifts value

July 4, 2022

Applause Entertainment Extends its Footprint in the South; Sets up an Office in Chennai

July 4, 2022
What's Hot

Türkiye’s anti-ship missile examined from cellular launcher for 1st time

July 4, 2022

£15bn deal for UK Power Networks collapses after proprietor lifts value

July 4, 2022

Applause Entertainment Extends its Footprint in the South; Sets up an Office in Chennai

July 4, 2022
Facebook Twitter Instagram
  • About Us
  • Contact
  • Add Post
  • Contribute For Us
  • Privacy Policy
  • Our Authors
Facebook Twitter LinkedIn
BusinessLendBusinessLend
  • NEWS
  • BUSINESS
  • AUTO
  • TECH
  • MONEY
  • STARTUP
  • SUCCESS STORIES
  • OTHER
    • Press Release
    • OPINION
Subscribe
BusinessLendBusinessLend
Home»NEWS»Indian Drugs Regulatory green signal to Sputnik V
NEWS

Indian Drugs Regulatory green signal to Sputnik V

Mirza ShehnazBy Mirza ShehnazApril 14, 2021No Comments4 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Indian Drugs Regulatory green signal to Sputnik V
Share
Facebook Twitter LinkedIn Pinterest Email

India’s drug regulator: Indian Drugs Controller General of India (DCGI) has approved Russia’s COVID-19 vaccine Sputnik-V for limited use in emergencies after being cleared by an expert panel. About 92 percent of the effective COVID-19 vaccine Sputnik-V may be available in India from the first fortnight of May. Speaking to reporters, Russian Direct Investment Fund (RDIF) CEO Kirill Dimitriv said, “By the end of April or the first week of May, some quantity of Sputnik V will be available in India.” He said that the top capacity of vaccines in India will be seen by July. He said that they are working closely with Indian companies and it is expected that more than 50 crore doses of Sputnik V will be prepared annually. Dimitriva said, “We have partnered with five companies and we are ready to partner with more companies.”

Hyderabad-based company Dr. Reddy’s Laboratories (DRL) has tied up with Russia’s Ministry of Health to obtain regulatory approval for the import of vaccines into India. This was approved by the Subject Expert Committee (SEC) on Monday. In an official statement, the Health Ministry said that after extensive deliberations, the SEC has recommended allowing limited use of this vaccine in emergencies subject to various regulatory provisions. According to a statement from the Ministry of Health of India, DRLA is collaborating with the National Research Center for Epidemiology and Microbiology of the Ministry of Health of Russia to get regulatory approval to import for marketing in India.

Russia vaccines have indicated active immunity to prevent COVID-19 disease in people over 18 years of age. Two doses of 0.5 ml of this vaccine should be given in the muscle at an interval of 21 days. This vaccine has to be stored at (-) 18 ° C. The vaccine has two components that cannot be replaced by each other. The Health Ministry said, ‘After careful consideration, the recommendations of the SEC have been accepted by the Controller General of Pharmaceuticals (India). DRL will import vaccines for use in the country. The National Regulatory Controller of India (DCGI) has so far approved two vaccines for emergency use (EUA). These include Kovishield prepared by Serum Institute of India (SII) and ‘Kovaxine’ vaccine prepared by Bharat Biotech International Limited (BBL). The Ministry of Health stated that several other vaccines are in various stages of clinical trials in the country.

“Dr. Reddy’s Laboratories Ltd. (DRL) had applied for permission to import and market Sputnik-V which has been produced by Russia’s Gamalaya Institute for limited use,” it said in a statement.

The gam-covid-vac vector vaccine (Component 1 and Component 2), popularly known as Sputnik-V, has been prepared by the National Research Center for Epidemiology and Microbiology of the Ministry of Health of Russia, and is developed in 30 countries around the world. Has been approved in. ‘ Interim results of the safety and efficacy of the safety and efficacy associated with Russia’s Phase III clinical trial have been published in the Lancet Journal. DRL was allowed to conduct Phase II and Phase III clinical trials in the country. The company has submitted interim data related to the ongoing second and third phase clinical trials in the country. The government said, “Clinical trial data is being continuously evaluated by CDSCO on the suggestion of the Subject Expert Committee (SEC) as a regulatory response.” The SEC consists of specialists with specialized knowledge in the fields of Pulmonology, Immunology, Microbiology, Pharmacology, Pediatrics, Internal Medicine etc. SEC important data including safety, immunity, data related to the impact of clinical trials abroad, age group, dosing time, caution, storage, warnings, adverse effects of special interest, risk benefit assessment, proposed factsheet, PI, SMPCETC Areas to be considered.

The SEC has also reviewed the approval given to the vaccine for its conditions / restrictions in Russia. The SEC said that the security and immunity offered by the companies in the Indian study could be compared with the interim data from Russia’s Phase III clinical trial. The SEC has, after extensive deliberations, recommended allowing limited use in emergencies subject to various regulatory provisions.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Mirza Shehnaz

Shehnaz Ali Siddiqui is a Corporate Communications Expert by profession and writer by Passion. She has experience of many years in the same. Her educational background in Mass communication has given her a broad base from which to approach many topics. She enjoys writing around Public relations, Corporate communications, travel, entrepreneurship, insurance, and finance among others.

Related Posts

Türkiye’s anti-ship missile examined from cellular launcher for 1st time

July 4, 2022

£15bn deal for UK Power Networks collapses after proprietor lifts value

July 4, 2022

Baku Int'l Sea Trade Port to increase infrastructure capacities of cargo visitors (Interview) (PHOTO/VIDEO)

July 4, 2022

UK motor insurers headed for underwriting losses as inflation bites

July 4, 2022

Minimising waste by means of prolonged producer accountability key to curb use of plastics – Indian Agency

July 4, 2022

Several useless in Copenhagen mall capturing

July 4, 2022
Add A Comment

Comments are closed.

Advertisement
Editors Picks

SEBI gives big relief to companies struggling with second wave of Corona, will get such benefits

April 30, 2021

Superplum Designs and Rolls out India's First Modern Litchi Supply Chain

June 8, 2022

Enamor Launches its Spring Summer Collection 2022

May 20, 2022

SankalpTaru Foundation becomes the First Indian NGO in Environmental Conservation Space to Launch Blockchain

April 3, 2022
Advertisement
Latest Posts

Türkiye’s anti-ship missile examined from cellular launcher for 1st time

July 4, 2022

£15bn deal for UK Power Networks collapses after proprietor lifts value

July 4, 2022

Applause Entertainment Extends its Footprint in the South; Sets up an Office in Chennai

July 4, 2022

Business Lend is a platform which brings executives officers, entrepreneurs, and venture capitalist together from different sectors. We keep on connecting with our users with the help of our monthly edition carving our way slowly towards the highest readership.

Facebook Twitter Instagram LinkedIn
Must Read
  • Türkiye’s anti-ship missile examined from cellular launcher for 1st time July 4, 2022
  • £15bn deal for UK Power Networks collapses after proprietor lifts value July 4, 2022
  • Applause Entertainment Extends its Footprint in the South; Sets up an Office in Chennai July 4, 2022

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

© 2022 BusinessLend. Designed by ThemeSphere.
  • About Us
  • Contact
  • Add Post
  • Contribute For Us
  • Privacy Policy
  • Our Authors

Type above and press Enter to search. Press Esc to cancel.